Sollis Therapeutics Information

At Sollis Therapeutics, we’re developing targeted interventional pain therapies with an initial focus on treating sciatica pain. We are dedicated to developing therapies that have the potential to replace off-label epidural steroid injections and opioids for the treatment of sciatica pain. Our novel Clonidine Micropellet (clonidine hydrochloride extended-release epidural micropellet) investigational therapy is designed to target the source of pain with an extended-release formulation of clonidine, a proven analgesic and anti-inflammatory. It is designed to provide rapid and durable pain relief. Clonidine combines both analgesic and anti-inflammatory effects. When delivered via our extended-release micropellet product candidate, this non-opioid, non-steroid medication is being developed for the treatment of pain associated with radiculopathy.